1. Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGF beta 1 Signaling
- Author
-
Lin lin Ji, Gui Jun Qin, Jacob van den Born, Qing zhu Wang, Jan-Luuk Hillebrands, Ting ting An, Feng juan Huang, Yan yan Zhao, Groningen Institute for Organ Transplantation (GIOT), and Groningen Kidney Center (GKC)
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,epithelial mesenchymal transition ,Renal function ,030209 endocrinology & metabolism ,PROGRESSION ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Diabetic nephropathy ,SGLT2 INHIBITORS ,03 medical and health sciences ,chemistry.chemical_compound ,Endocrinology ,0302 clinical medicine ,STAT1 ,Downregulation and upregulation ,Internal medicine ,TGF-β1 ,Renal fibrosis ,Medicine ,tubulointerstitial fibrosis ,Dapagliflozin ,Original Research ,lcsh:RC648-665 ,business.industry ,dapagliflozin ,medicine.disease ,Streptozotocin ,EPITHELIAL-MESENCHYMAL TRANSITION ,030104 developmental biology ,chemistry ,Tubulointerstitial fibrosis ,SGLT2 Inhibitor ,business ,TGF-beta 1 ,medicine.drug - Abstract
Tubulointerstitial fibrosis (TIF) plays an important role in the progression of renal fibrosis in diabetic nephropathy (DN). Accumulating evidence supports a crucial inhibitory effect of dapagliflozin, a SGLT2 inhibitor, on TIF, but the underlying mechanisms remain largely unknown. This study aimed to shed light on the efficacy of dapagliflozin in reducing TIF as well as its possible impact on renal function. TIF in human kidney biopsies obtained from patients with DN was quantified by histopathological staining. In vitro, HK-2 cells were incubated in high glucose with dapagliflozin or fludarabine, and epithelial-mesenchymal transition (EMT) was determined. In vivo experiments were performed in streptozotocin (STZ)-induced type 1 diabetic mice treated with dapagliflozin by gavage for 16 weeks, after which specific functional characteristics and TIF were analyzed. In both DN patients and diabetic mice, fibronectin and Col IV, as well as STAT1 protein in the kidneys were increased as compared with controls. Dapagliflozin significantly decreased blood glucose, and renal STAT1 and TGF-beta 1 expression in mice. Furthermore, dapagliflozin improved renal function, and attenuated diabetes-induced TIE In HK-2 cells, dapagliflozin, and fludarabine directly decreased aberrant STAT1 expression and reversed high glucose-induced downregulation of E-cadherin and a-SMA induction. Thus, the results demonstrate that dapagliflozin not only improves hyperglycemia but also slows down the progression of diabetes-associated renal TIF by improving hyperglycemia-induced activation of the STAT1/TGF-beta 1 pathway.
- Published
- 2019